TABLE 1.

The BCSCs Surface markers in significant literatures.

Surface markers	Mediated signaling	Function in BC
CD44 (Al-Hajj et al., 2003)	PI3K/AKT signaling (Ghatak et al., 2002)	Forming tumors (Al-Hajj et al., 2003), promoting metastasis (Hill et al., 2006), associated with (BRCA1) mutational status (Bane et al., 2013) Predicting prognosis (Bane et al., 2013), stimulating migration (Bourguignon et al., 2003), promoting cell adhesion (Ponta et al., 2003), promoting. Cell growth, survival, and invasion (Louderbough and Schroeder, 2011)
	NF-κB signaling (Cho et al., 2015)
	CREB/TGF-β2 signaling (Ouhtit et al., 2018)
ALDH1 (Ginestier et al., 2007)		Associated to tumor-initiating characteristics (Ginestier et al., 2007), promoting self-renewal (Ginestier et al., 2009), As target for BCSCs-targeted therapy (Angeloni et al., 2015) Predicting prognosis 11823860 (Alexe et al., 2006; van’t Veer et al., 2002) promoting metastasis (Marcato et al., 2011)
CD133	IL6/Notch3 signaling (Sansone et al., 2016)	Regulation of ET-resistant (Sansone et al., 2016) promoting self-renewal (Sansone et al., 2016) BCSCs identification (Bai et al., 2018)
		CD133 aptamers or CD133-targeted drug delivery system for BCSCs-targeted therapy (Shigdar et al., 2013; Swaminathan et al., 2013)
EpCAM		Regulation of migration and metastasis (Baccelli et al., 2013) promoting chemoresistance (Wang T. et al., 2015)
ABCG2		Promoting BC chemoresistance, tumorigenicity and metastasis (Bai et al., 2018), Sorting BCSCs from BRCA1-mutated BC cells (Leccia et al., 2014)
GD2		Aassociated with GD3S-mediated EMT (Liang et al., 2017), promoting tumorigenicity and metastasis (Battula et al., 2017),BCSCs. identification (Bai et al., 2018)
CXCR4	SDF-1/CXCR4 signaling (Yi et al., 2014)	Promoting metastasis (Muller et al., 2001), promoting migration or invasion (Luker et al., 2012)